Allergy Therapeutics Share Price (AGY)

25.25 +1.25 (+5.21%) delayed: 11:53PM GMT
Bid price 25.00 Open price 24.00
Ask price 25.50 Prev close 25.25
High price 25.49 Spread 1.96%
Low price 23.75 Volume 470,792

Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.

Allergy Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Allergy Therapeutics share price charts

Allergy Therapeutics Share Price Information

Name Allergy Therapeutics Epic AGY
Sector Pharmaceuticals & Biotechnology ISIN GB00B02LCQ05
Activites Allergy Therapeutics plc is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging markets. Index n/a

Allergy Therapeutics Key Numbers

Latest Share Price (p) 25.25 Net Gearing (%) 5.20
Market Capitalisation (£m) 142.43 Gross Gearing (%) 46.50
Shares in issue (m) 593.44 Debt Ratio 31.33
P/E Ratio -10.48 Debt-to-Equity Ratio 0.53
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.87
Dividend Yield (%) 0.00 Price to book value 4.70
Dividend cover (x) 0.00 ROCE (%) -27.31
Earning per share (p) -2.29 EPS Growth (%) -11,550.00
52 week high / low 28.38 / 16.38 DPS Growth (%) n/a

Allergy Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
29/09/2016 BUY Peter Jensen CH 30,000
28/09/2016 BUY Nick Wykeman FD 150,000
26/09/2016 BUY Manuel Llobet CEO 100,000
27/07/2015 BUY Manuel Llobet CEO 50,000
10/12/2012 EXR Ian Postlethwaite RES 1,500,000

More Allergy Therapeutics Director Deals >>

Allergy Therapeutics Company News

07:15 20/01/2017

Hardman Research: Investment driving market share

RNS Number : 6686U Allergy Therapeutics PLC 20 January 2017   Hardman Research: Investment driving market share gains Investment driving market share gains : AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro...

11:10 19/01/2017

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 43p (from 40p). Story provided by

09:27 19/01/2017

Allergy Therapeutics revenues up

Allergy Therapeutics expects reported revenues for the six months ended 31 December to be £40.4m - representing 17.9% organic growth at constant currency and 39.3% growth on a reported basis, aided by the impact on euro revenues of the weak pound. The group said this growth reflected continued...

More Allergy Therapeutics Company News >>

Register now for FREE Allergy Therapeutics company news

Allergy Therapeutics Share Price Discussions

04 hours ago

Allergy Therapeutics PLC (AGY)

Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....

8 months ago

Allergy TV Clip re: Successful Phase II Study (AGY)

10 months ago

Allergy Therapeutics (AGY)

Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results.

Register now for FREE Allergy Therapeutics share price discussions